Alcon, the global leader in eye care and a division of Novartis, is launching a new consumer education campaign called Invisible Edge with the help of Olympic gold- and silver-medalist Laurie Hernandez and two-time gold-medalist Tobin Heath. These star athletes will be shining a spotlight on the importance of clear vision, including the role of top-performing Alcon DAILIES® contact lenses in helping give “everyday” athletes an edge while competing at any level. The Invisible Edge campaign is based on a new survey that found clear eyesight tops the list of attributes that help nearly three in four “everyday” athletes perform at their best.
To view the multimedia release go to:
https://www.multivu.com/players/English/8184651-alcon-dailies-us-olympians/
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old.
In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors.
To view the multimedia release go to:
https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
